MaurieMarkmanMD

Obstetrics & Gynecology • Houston, TX

Gynecologic Oncology

Physician

Join to view full profile

Dr. Markman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Markman's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

NYU Grossman School of MedicineResidency, Internal Medicine, 1974 - 1978
New York University School of MedicineClass of 1974
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology

Certifications & Licensure

CA State Medical License 2002 - Present
PA State Medical License 2001 - 2024
GA State Medical License 2012 - 2015
TX State Medical License 2006 - 2012
MI State Medical License 2002 - 2006
OH State Medical License 1992 - 2006
IL State Medical License 2002 - 2005
MD State Medical License 1978 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Fellow (FASCO) American Society of Clinical Oncologists, 2011

Clinical Trials

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Start of enrollment: 1997 Nov 01
Completed
Phase 3
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum Start of enrollment: 1997 Sep 01
Unknown status
Phase 2
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Jul 01
Terminated
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy Start of enrollment: 2007 Oct 01
Withdrawn
Not Applicable
Join now to see all

Publications & Presentations

PubMed

4 citations
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors i...
Omali Pitiyarachchi, Michael Friedlander, James J Java, John K Chan, Deborah K Armstrong
Gynecologic Oncology. 2022-09-01
16 citations
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Katherine Fuh, James J. Java, John K. Chan, Daniel S. Kapp, Bradley J. Monk
Gynecologic Oncology. 2019-08-01
9 citations
Pharmaceutical Management of Ovarian Cancer: Current Status.
Maurie Markman
Drugs. 2019-07-01

Other

Intraperitoneal chemotherapy for treatment of ovarian cancer
Markman M, Walker JL
http://www.uptodate.com/contents/intraperitoneal-chemotherapy-for-treatment-of-ovarian-cancer
UpToDate, Wolters Kluwer Health - 2012-06-14

Press Mentions

Disrupting the Status Quo: We Need More Pragmatic TrialsDecember 23rd, 2024
Does Cancer Stage Shift Correlate with Long-Term Survival?December 10th, 2024
Only 7% of Patients with Cancer Participate in Clinical Trials: Far from AdequateNovember 13th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow